Cognition Therapeutics Q2 net loss narrows on lower R&D costs

Cognition Therapeutics

06/08/2026 21:26

Overview
US clinical-stage biopharma's Q2 net loss narrowed as R&D expenses declined sharply
Company ended Q2 with $34.8 mln in cash, expects to fund operations into Q4 2027
Progress made on planned Phase 3 trial for DLB psychosis; new zervimesine patent allowance could extend protection through 2045

Outlook
Company did not provide specific financial guidance for the current or future periods

Result Drivers
LOWER R&D SPENDING - Co said decrease in research and development expenses was due to reduced trial activities, compensation and professional fees
HIGHER ADMIN COSTS - Increase in general and administrative expenses attributed to higher professional fees

Company press release: ID:nGNX3jDWFb

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$3.93 mln
 
Q2 Loss From Operations
 
-$7.74 mln
 
Q2 Operating Expenses
 
$7.74 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Cognition Therapeutics Inc is $3.00, about 183% above its August 5 closing price of $1.06

Reuters Recommended Reads
Aug 6 - ALX Oncology Q2 net loss narrows on lower R&D costs
Aug 5 - Biomea Fusion Q2 loss narrows, cash runway into Q2 2027
Aug 6 - Prime Medicine Q2 net loss narrows on lower expenses

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)